---
title: "JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263340862.md"
description: "According to the Zhitong Finance APP, JAFRON released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.556 billion yuan, a year-on-year decrease of 29.13%. The net profit attributable to shareholders of the listed company was 453 million yuan, a year-on-year decrease of 42.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 438 million yuan, a year-on-year decrease of 41.87%. The basic earnings per share were 0.59 yuan"
datetime: "2025-10-29T16:11:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263340862.md)
  - [en](https://longbridge.com/en/news/263340862.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263340862.md)
generator: "portal-rs"
---

# JAFRON released its performance for the first three quarters, with a net profit attributable to the parent company of 453 million yuan, a decrease of 42.75%

According to the Zhitong Finance APP, JAFRON (300529.SZ) released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 1.5556 billion yuan, a year-on-year decrease of 29.13%. The net profit attributable to shareholders of the listed company was 453 million yuan, a year-on-year decrease of 42.75%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 438 million yuan, a year-on-year decrease of 41.87%. The basic earnings per share were 0.59 yuan

### Related Stocks

- [300529.CN](https://longbridge.com/en/quote/300529.CN.md)

## Related News & Research

- [10:44 ETHearingLife Introduces Oticon Reveal, the World's First Dual AI-Powered Hearing Aid](https://longbridge.com/en/news/296804127.md)
- [US health agencies report 55 cases of E. coli and salmonella infections tied to alfalfa sprouts](https://longbridge.com/en/news/296645342.md)
- [SalMar – Record-strong biological performance](https://longbridge.com/en/news/296859687.md)
- [Liminatus Pharma taps Synex as CRO for IBC101 Phase 1/2a study in South Korea](https://longbridge.com/en/news/296784834.md)
- [Vector Science begins pharma-grade peptide production at first LyoGenesis suite, targets 55,000 vials a month](https://longbridge.com/en/news/296780586.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**